Plans to expand African vaccine production face steep hurdles
In March 2022, when the pandemic was still raging, the messenger RNA (mRNA) company Moderna announced it would build a $500 million plant in Kenya to manufacture half a billion doses of its COVID-19 vaccine annually. “
This is major
,” Kenyan President William Ruto said at the time. The plant would help reduce Africa’s dependence on vaccines produced elsewhere, Ruto said—a situation that had turned disastrous during the pandemic—and bring economic benefits as well.
But Moderna may never break ground on the Kenya factory. On 11 April, the company said it had
“paused its efforts”
becau...
Source: Science of Aging Knowledge Environment - April 16, 2024 Category: Geriatrics Source Type: research
Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Neisseria gonorrhoeae infection in men who have sex with men: the GoGoVax study protocol
This study will evaluate the efficacy of 4CMenB against N. gonorrhoeae infection in men (cis and trans), transwomen and non-binary people who have sex with men (hereafter referred to as GBM+).
Methods and analysis
This is a double-blind, randomised placebo-controlled trial in GBM+, either HIV-negative on pre-exposure prophylaxis against HIV or living with HIV (CD4 count >350 cells/mm3), who have had a diagnosis of gonorrhoea or infectious syphilis in the last 18 months (a key characteristic associated with a high risk of N. gonorrhoeae infection). Participants are randomised 1:1 to receive two doses of 4CMenB or placeb...
Source: BMJ Open - April 16, 2024 Category: General Medicine Authors: Seib, K. L., Donovan, B., Thng, C., Lewis, D. A., McNulty, A., Fairley, C. K., Yeung, B., Jin, F., Fraser, D., Bavinton, B. R., Law, M., Chen, M. Y., Chow, E. P. F., Whiley, D. M., Mackie, B., Jennings, M. P., Jennison, A. V., Lahra, M. M., Grulich, A. E. Tags: Open access, Infectious diseases Source Type: research
Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland
CONCLUSIONS: These results demonstrate that using PCV15 among adults aged 65 years-and-above can prevent a substantial number of PD cases and deaths while remaining cost-effective over a range of inputs and scenarios.PMID:38609806 | DOI:10.1016/j.vaccine.2024.04.016 (Source: Vaccine)
Source: Vaccine - April 12, 2024 Category: Allergy & Immunology Authors: Kwame Owusu-Edusei Andrea Favre-Bulle Eleana Tsoumani Thomas Mutschler Nicole Cossrow Source Type: research
Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland
CONCLUSIONS: These results demonstrate that using PCV15 among adults aged 65 years-and-above can prevent a substantial number of PD cases and deaths while remaining cost-effective over a range of inputs and scenarios.PMID:38609806 | DOI:10.1016/j.vaccine.2024.04.016 (Source: Vaccine)
Source: Vaccine - April 12, 2024 Category: Allergy & Immunology Authors: Kwame Owusu-Edusei Andrea Favre-Bulle Eleana Tsoumani Thomas Mutschler Nicole Cossrow Source Type: research
Vaccines in cardiology, an underutilized strategy to reduce the residual cardiovascular risk
Arch Peru Cardiol Cir Cardiovasc. 2024 Mar 19;5(1):29-39. doi: 10.47487/apcyccv.v5i1.349. eCollection 2024 Jan-Mar.ABSTRACTCardiovascular diseases stand as the leading cause of mortality among adults globally. For decades, comprehensive evidence has underscored the correlation between infections, particularly those involving the respiratory system, and an elevated risk of cardiovascular and cerebrovascular events, as well as all-cause mortality. The mechanisms through which infections heighten cardiovascular events are intricate, encompassing immune system activation, systemic inflammation, hypercoagulable states, sympathe...
Source: Herpes - April 10, 2024 Category: Infectious Diseases Authors: Sebasti án García-Zamora Laura Pulido Source Type: research
Enhancing Immune Response in Non-Small-Cell Lung Cancer Patients: Impact of the 13-Valent Pneumococcal Conjugate Vaccine
Conclusions: We hope that our research will contribute to increasing patients' and physicians' awareness of the importance of including PCV13 vaccinations in the standard of oncological care, which will extend the survival time of patients and improve their quality of life.PMID:38592328 | DOI:10.3390/jcm13051520 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Jolanta Smok-Kalwat Paulina Mertowska Izabela Korona-G łowniak Sebastian Mertowski Paulina Nied źwiedzka-Rystwej Dominika B ębnowska Krzysztof Gosik Andrzej Stepulak Stanis ław Góźdź Jacek Roli ński Zofia G órecka Jan Siwiec Ewelina Grywalska Source Type: research
Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
CONCLUSION: Full vaccination coverage in Swiss children is still below 90 % with many vaccinations administered delayed. Given regional differences, missed or delayed booster vaccinations, and differences in vaccine-specific acceptability, more effort may be needed to achieve national vaccination targets.PMID:38593195 | DOI:10.1016/j.vaccine.2023.10.043 (Source: Vaccine)
Source: Vaccine - April 9, 2024 Category: Allergy & Immunology Authors: Simeon J Z ürcher Andri Signorell Anja L échot-Huser Christoph Aebi Carola A Huber Source Type: research
Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence
CONCLUSIONS: PCV13 had a certain protective effect on all-cause hospitalized pneumonia, and the booster immunization strategy had the best protective effect with great public health significance to enter the immunization program.PMID:38594120 | DOI:10.1016/j.vaccine.2024.04.015 (Source: Vaccine)
Source: Vaccine - April 9, 2024 Category: Allergy & Immunology Authors: Min Lv Juan Du Ming-Zhu Xie Yiguo Zhou Guangzhao Yang Jian Wang Wan-Xue Zhang Han Yang Shan-Shan Zhang Fuqiang Cui Qing-Bin Lu Jiang Wu Source Type: research
Enhancing Immune Response in Non-Small-Cell Lung Cancer Patients: Impact of the 13-Valent Pneumococcal Conjugate Vaccine
Conclusions: We hope that our research will contribute to increasing patients' and physicians' awareness of the importance of including PCV13 vaccinations in the standard of oncological care, which will extend the survival time of patients and improve their quality of life.PMID:38592328 | PMC:PMC10933946 | DOI:10.3390/jcm13051520 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Jolanta Smok-Kalwat Paulina Mertowska Izabela Korona-G łowniak Sebastian Mertowski Paulina Nied źwiedzka-Rystwej Dominika B ębnowska Krzysztof Gosik Andrzej Stepulak Stanis ław Góźdź Jacek Roli ński Zofia G órecka Jan Siwiec Ewelina Grywalska Source Type: research
Adherence to Advisory Committee on Immunization Practices in diabetes mellitus patients in Saudi Arabia: A multicenter retrospective study
CONCLUSION: In Saudi Arabia, patients with DM showed higher vaccination rates for annual influenza and COVID-19 vaccines compared to other vaccinations such as herpes zoster, Tdap, pneumococcal, and HPV. Factors such as vaccine recommendations provided by family physicians or specialists, the site of care, income level, DM-related hospitalization history, residency site, HbA1c level, and health sector type can significantly influence the vaccination rate in patients with DM.PMID:38591075 | PMC:PMC10999047 | DOI:10.4239/wjd.v15.i3.440 (Source: Herpes)
Source: Herpes - April 9, 2024 Category: Infectious Diseases Authors: Saleh Fahad Alqifari Aya K Esmail Dalal M Alarifi Ghalya Y Alsuliman Maram M Alhati May R Mutlaq Mohammed Aldhaeefi Shaden A Alshuaibi Palanisamy Amirthalingam Abrar Abdallah Afaf S Wasel Heba R Hamad Shoroq Alamin Tasneem H Atia Tariq Alqahtani Source Type: research
Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
CONCLUSION: Full vaccination coverage in Swiss children is still below 90 % with many vaccinations administered delayed. Given regional differences, missed or delayed booster vaccinations, and differences in vaccine-specific acceptability, more effort may be needed to achieve national vaccination targets.PMID:38593195 | DOI:10.1016/j.vaccine.2023.10.043 (Source: Vaccine)
Source: Vaccine - April 9, 2024 Category: Allergy & Immunology Authors: Simeon J Z ürcher Andri Signorell Anja L échot-Huser Christoph Aebi Carola A Huber Source Type: research
Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence
CONCLUSIONS: PCV13 had a certain protective effect on all-cause hospitalized pneumonia, and the booster immunization strategy had the best protective effect with great public health significance to enter the immunization program.PMID:38594120 | DOI:10.1016/j.vaccine.2024.04.015 (Source: Vaccine)
Source: Vaccine - April 9, 2024 Category: Allergy & Immunology Authors: Min Lv Juan Du Ming-Zhu Xie Yiguo Zhou Guangzhao Yang Jian Wang Wan-Xue Zhang Han Yang Shan-Shan Zhang Fuqiang Cui Qing-Bin Lu Jiang Wu Source Type: research
Prior pneumococcal vaccination improves in-hospital mortality among elderly population hospitalized due to community-acquired pneumonia
Pneumococcal vaccination is a preventive method to reduce pneumonia related mortality. However, real-world data on efficacy of the pneumococcal vaccine in reducing mortality is lacking, especially in elderly p... (Source: BMC Pulmonary Medicine)
Source: BMC Pulmonary Medicine - April 8, 2024 Category: Respiratory Medicine Authors: Seohyun Kim, Moon Jin Kim, Jun-Pyo Myong, Yun-Hee Lee, Bo Yeon Kim, Ahyoung Hwang, Gui Ok Kim, Sung Hwan Jeong, Hyoung Kyu Yoon, Tai Joon An and Jeong Uk Lim Tags: Research Source Type: research
Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13
CONCLUSIONS: Changes in uptake of PCV13 and PPV23 among those aged 70 + years were consistent with program changes. However, PCV13 uptake was still substantially lower in individuals aged 65-69 years overall and in those with comorbidities.PMID:38584056 | DOI:10.1016/j.vaccine.2024.04.012 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Fariha Binte Hossain David Muscatello Sanjay Jayasinghe Jitendra Jonnagaddala Bette Liu Source Type: research
Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13
CONCLUSIONS: Changes in uptake of PCV13 and PPV23 among those aged 70 + years were consistent with program changes. However, PCV13 uptake was still substantially lower in individuals aged 65-69 years overall and in those with comorbidities.PMID:38584056 | DOI:10.1016/j.vaccine.2024.04.012 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Fariha Binte Hossain David Muscatello Sanjay Jayasinghe Jitendra Jonnagaddala Bette Liu Source Type: research
